Targeting TGFβ2 Distal Enhancers for Fibrotic Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Scleroderma and other TGFβ2-associated diseases are limited due to a lack of understanding of the genetic and molecular mechanisms, leading to non-specific symptomatic management with varying efficacy, and there is a need for targeted therapies to address fibrosis and inflammation.
Innovation Solution
The development of compositions and methods that modulate TGFβ2 expression by targeting enhancer sequences distal to the TGFβ2 locus, using agents such as histone deacetylase inhibitors, BRD4 inhibitors, and CRISPR/Cas agents to inhibit or activate specific epigenetic marks at these sequences, thereby regulating TGFβ2 expression and associated fibrotic processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-specific symptomatic management is used for Scleroderma, then treatment coverage is broad, but efficacy against fibrosis is insufficient
Solution Approach 1:
The patent segments the broad non-specific treatment approach into targeted therapies that specifically address TGFβ2-driven fibrotic pathways. By identifying and targeting the specific molecular mechanism (TGFβ2 expression regulated by distal enhancer elements), the treatment transitions from general symptomatic management to precise mechanism-based therapy, thereby improving efficacy against fibrosis while maintaining adaptability through multiple targeted approaches (small molecules, biologics, gene therapy).
2Reliability
If targeted therapy against distal enhancer sequences is developed, then efficacy against TGFβ2-associated diseases is improved, but understanding of genetic and molecular mechanisms is required
Solution Approach 1:
The patent uses distal enhancer sequences as intermediary targets between the complexity of genetic mechanisms and the simplicity of drug delivery. These enhancer elements serve as accessible, external regulatory points that can be targeted by various therapeutic modalities (small molecules, antibodies, oligonucleotides) without requiring direct manipulation of the complex TGFβ2 gene structure. This intermediary approach simplifies the therapeutic strategy while maintaining high efficacy.
3Reliability
If multiple agents targeting different epigenetic mechanisms are used, then treatment effectiveness is improved, but device complexity increases
Solution Approach 1:
The patent merges multiple epigenetic targeting mechanisms (histone deacetylase inhibition, bromodomain inhibition, CRISPR-based epigenetic editing) into a unified therapeutic strategy focused on distal enhancer regulation. Rather than treating these as separate complex interventions, they are integrated as complementary approaches that converge on the same molecular target (TGFβ2 distal enhancers), thereby improving treatment effectiveness while managing complexity through a common strategic framework.
Data Source
AI summary
The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGFβ2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGFβ2-associated diseases, disorders and/or conditions.